The MoveS-it Study (Multiple Sclerosis Study of ANK-700 to Assess Safety and Immune Tolerance) is a randomized, double-blind, placebo-controlled, first-in-human study designed to evaluate the safety and tolerability of single and multiple ascending doses of ANK-700.
MS is a demyelinating disease of the central nervous system, in which the immune system attacks the myelin sheath in the brain and spinal cord.
ANK-700 aims to re-educate the immune system by inducing antigen-specific tolerance to myelin-based autoantigens in order to reduce neuroinflammation in the brain and spinal cord.
The MoveS-it Study will enroll up to 40 patients at up to 10 sites across the United States.
The primary endpoint of the trial is safety and tolerability, the secondary endpoint is pharmacokinetics of ANK-700, and other exploratory endpoints include assessments of immunological biomarker responses.
Anokion SA is a Swiss biotechnology company targeting autoimmune diseases.
The company is focused on both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis and type 1 diabetes.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca